Cystic FibrosisNCT01987271
Effects Of Noninvasive Ventilation On Functional Capacity Of Patients With Cystic Fibrosis
A study testing Noninvasive Ventilation in people with Cystic Fibrosis, run by Universidade Federal de Pernambuco at 1 site in Brazil.
Trial summary
The purpose of this study is to evaluate the effect of noninvasive ventilation (NIV) in functional capacity of children and adolescents with cystic fibrosis. Read more about this study
- Who is it for?
- Ages 7 to 16 years
- Conditions the study is for
- Cystic Fibrosis
- What is being tested?
- Noninvasive Ventilation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteBrazil
- Study dates
- Aug 2012to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- clinical diagnosis of Cystic Fibrosis
- FEV1< 80% of predicted
- age between 7 and 16 years
- clinically stable patients
- no history of hospitalization for respiratory failure in the last three months
Who cannot join
- recent history of hemoptysis
- pneumothorax or evidence of emphysomatous bubbles detected by chest X-ray
- Burkholderia cepacia colonization
- the need for more than two physiotherapy sessions per day
- gastroesophageal reflux
- orthopedic trauma or cardiovascular conditions that impede the treadmill walk test
- heart failure
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Instituto de Medicina Intergral Prof. Fernando Fiqueira
Recife, Pernambuco, 50070-550
About this study
Official title: Effects Of Noninvasive Ventilation During The Treadmill Walking Test On Cardiorespiratory System, Walk Distance, And Thoracoabdominal Kinematics Of Patients With Cystic Fibrosis: Clinical Randomized Controlled Trial.
The purpose of this study is to evaluate the effect of noninvasive ventilation (NIV) in functional capacity of children and adolescents with cystic fibrosis.
Read the detailed description
This is an open randomized controlled crossover clinical trial. Sample selection was by convenience and patients were screened at the Pneumology outpatient facility of the Instituto de Medicina Integral Professor Fernando Figueira (IMIP) in Recife, Brazil.
The sample was calculated using a software developed by the MGH Mallinckrodt General Clinical Research Center, based on the results of the first 10 volunteers, for a statistical power of detecting differences between procedures of 80% and a significance level of 0.05. A sample size of n=13 patients was determined, considering that the real difference between the walk distance between procedures with and without NIV is 0.03 km and the standard deviation of the differences in variables is 0.034 km.
All patients agreed to take part in the study by giving their informed consent, in accordance with resolution 196/96 of the National Health Council.
Technical Procedures Patients were initially assessed for current and past conditions, medication use and anthropometric data (height, weight and body mass index - BMI). Next, a randomized plan was compiled using the Web Site Randomization.com, applying a generator of random-permuted blocks to define the order in which patients would execute the 6MWT, with or without NIV. Patients allocated to group 1 (G1) initiated the 6MWT without NIV to subsequently perform the test with ventilatory support, since those allocated to group 2 (G2) underwent the tests in reverse order. A minimum and maximum rest period of 24 and 48 hours, respectively, was observed between tests.
Before and after the 6MWT with and without NIV, patients were assessed for variations in compartmental chest wall volume and ventilatory pattern by optoelectronic plethysmography (OEP), which was followed by the spirometric test. A 20-minute rest period was given after the pulmonary function test before proceeding to the 6MWT.
6-minute walk test on the treadmill: Prior to the test, the patient was familiarized with the treadmill (G-635, Pro Action BH-fitness- Germany) and instructed about test procedures in accordance with ATS guidelines22. The following parameters were assessed before, immediately after and in the 5th minute post-test: blood pressure (BP), respiratory rate (RR), heart rate (HR), Borg's scale (BS) and peripheral O2 saturation (SpO2). HR, RR and SpO2 were also monitored minute by minute during the test, such that a drop in SpO2 below 87% or rise in RR to more than 75% of age-predicted maximal HR were used as criteria for interrupting the test. The test initiated with the treadmill traveling at 2.5 km/h. Every 30 seconds of the test, the examiner asked the patient if the speed could be increased, maintained or decreased, and patients answered using previously agreed upon signals. The speed could not exceed 7 km/h and if it was reached, the question would be re-asked in the next 30 seconds to determine whether the speed would be maintained or reduced. After the test, the walk distance (WD) on the treadmill was recorded.
The 6MWT performed with NIV followed the same procedures described above. However, before the test, patients were submitted to NIV on a BiPAP mode (Synchrony- Respironics, Brazil) for 30 minutes, as proposed by Serra et al 15, with inspiratory airway pressure (IPAP) level of 12 cmH2O and final expiratory airway pressure (EPAP) of 6 cmH2O, which can vary by 2 cmH2O more or less depending on the patient's comfort. In the last six minutes of BiPAP the patient performed the 6MWT with the ventilatory support.
Optoelectronic plethysmography: The individual was sitting with 89 retro-reflective sensors at specific thoracic and abdominal points. Eight cameras were arranged around the patient for a three-minute film of quiet breathing. The images were analyzed in a three-dimensional polyhedric model using OEP capture software (BTS Bioengineering, Italy). The following variables were assessed by OEP (BTS Bioengineering, Italy) before and after both tests, with and without NIV: tidal volume, pulmonary rib cage volume, abdominal rib cage and abdominal volume (VC, Vrcp Vrca, Vab), respiratory rate (RR), inspiratory time (Ti), expiratory time (Te) total ventilatory cycle time (Ttot) and duty cycle, which represents the Ti/Ttot ratio.
Spirometry: Spirometry was conducted using a Microloop MK 8 spirometer (Micro Medical, England) to assess pulmonary function response, considering a 20-minute rest period between the spirometric test and 6MWT. Three reproducible forced maneuvers that met American Thoracic Society criteria were performed. The highest values obtained for forced expiratory volume in the first minute (FEV1), forced vital capacity (FVC), forced vital capacity between 25-75% of FVC (FEF 25-75) were recorded for analysis.
- Conditions
- Cystic Fibrosis
- Being tested
- Noninvasive Ventilation
- Keywords
- exercise tolerance, exercise test, noninvasive ventilation
- Medical subject headings
- Cystic Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Noninvasive VentilationDevice
Also called BiLEVEL, Noninvasive ventilatory support
A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
| Study group | Role | What they receive |
|---|---|---|
| With noninvasive ventilation | Experimental | When patients do the six minute walk test with the noninvasive ventilation. Receives: Device: Noninvasive Ventilation |
| Without noninvasive ventilation | No intervention | When patients do the six minute walk test without noninvasive ventilation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Walk Distance (WD) on six minute walk test (6MWT)
Patients allocated to group 1 (G1) initiated the 6MWT without noninvasive ventilation (NIV) to subsequently perform the test with ventilatory support, since those allocated to group 2 (G2) underwent the tests in reverse order. Rest period between tests: 24 - 48 hours. At the end of the test, the walk distance on a treadmill is recorded.
Measured: 2 days
Secondary outcomes (5)
Forced expiratory volume in the first second (FEV1)
The patients do the walk test a twice on a week. Before and after each test, this variable is recorded.
Measured: 2 days
Rib cage volumes
This variable is assessed by Optoeletronic Pletismography (BTS Bioengineering, Italy) before and after both tests, with and without NIV, recording the tidal volume, pulmonary rib cage volume, abdominal rib cage and abdominal volume (Vt, Vrcp Vrca, Vab).
Measured: 2 days
Forced vital capacity (FVC)
The patients do the walk test a twice on the same week. Before and after each test, this variable is recorded.
Measured: 2 days
Forced expiratory flow of 25% to 75% of FVC (FEF 25-75)
The patients do the walk test a twice on the same week. Before and after each test, this variable is recorded.
Measured: 2 days
Respiratory cicle time
This following variable is assessed by Optoeletronic Pletismography (BTS Bioengineering, Italy) before and after both tests, with and without NIV, recording the respiratory rate (RR), inspiratory time (Ti), expiratory time (Te), total ventilatory cycle time (Ttot) and duty cycle, which represents the Ti/Ttot ratio.
Measured: 2 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2013 (estimated)
- Study startAug 2012
- Primary completionJan 2013
- Study completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cystic FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade Federal de Pernambuco
- Sponsor type
- University, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
- Responsible party
- Principal investigator, Cibelle Andrade Lima, Universidade Federal de Pernambuco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01987271
- Sponsor's protocol ID
- 0.381.0.172.099-11
- Status last verified
- Nov 2013
- First submitted
- 4 Nov 2013
- Last updated
- 19 Nov 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Engelsbel S, Kuijper EJ, Dankert J, Braat MC, Egas J. [A tuberculosis project in Ecuador]. Ned Tijdschr Geneeskd. 1991 Dec 21;135(51):2428-32. Dutch.
PubMed 1758504Aliverti A, Cala SJ, Duranti R, Ferrigno G, Kenyon CM, Pedotti A, Scano G, Sliwinski P, Macklem PT, Yan S. Human respiratory muscle actions and control during exercise. J Appl Physiol (1985). 1997 Oct;83(4):1256-69. doi: 10.1152/jappl.1997.83.4.1256.
PubMed 9338435
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects Of Noninvasive Ventilation During The Treadmill Walking Test On Cardiorespiratory System, Walk Distance, And Thoracoabdominal Kinematics Of Patients With Cystic Fibrosis: Clinical Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT01987271
- Acronym / sponsor ID
- 0.381.0.172.099-11
- Conditions
- Cystic Fibrosis
- Keywords
- exercise tolerance, exercise test, noninvasive ventilation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Universidade Federal de PernambucoUniversity, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
- Study start
- Aug 2012
- Primary completion
- Jan 2013 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 19 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effect of noninvasive ventilation (NIV) in functional capacity of children and adolescents with cystic fibrosis.
Detailed description
This is an open randomized controlled crossover clinical trial. Sample selection was by convenience and patients were screened at the Pneumology outpatient facility of the Instituto de Medicina Integral Professor Fernando Figueira (IMIP) in Recife, Brazil.
The sample was calculated using a software developed by the MGH Mallinckrodt General Clinical Research Center, based on the results of the first 10 volunteers, for a statistical power of detecting differences between procedures of 80% and a significance level of 0.05. A sample size of n=13 patients was determined, considering that the real difference between the walk distance between procedures with and without NIV is 0.03 km and the standard deviation of the differences in variables is 0.034 km.
All patients agreed to take part in the study by giving their informed consent, in accordance with resolution 196/96 of the National Health Council.
Technical Procedures Patients were initially assessed for current and past conditions, medication use and anthropometric data (height, weight and body mass index - BMI). Next, a randomized plan was compiled using the Web Site Randomization.com, applying a generator of random-permuted blocks to define the order in which patients would execute the 6MWT, with or without NIV. Patients allocated to group 1 (G1) initiated the 6MWT without NIV to subsequently perform the test with ventilatory support, since those allocated to group 2 (G2) underwent the tests in reverse order. A minimum and maximum rest period of 24 and 48 hours, respectively, was observed between tests.
Before and after the 6MWT with and without NIV, patients were assessed for variations in compartmental chest wall volume and ventilatory pattern by optoelectronic plethysmography (OEP), which was followed by the spirometric test. A 20-minute rest period was given after the pulmonary function test before proceeding to the 6MWT.
6-minute walk test on the treadmill: Prior to the test, the patient was familiarized with the treadmill (G-635, Pro Action BH-fitness- Germany) and instructed about test procedures in accordance with ATS guidelines22. The following parameters were assessed before, immediately after and in the 5th minute post-test: blood pressure (BP), respiratory rate (RR), heart rate (HR), Borg's scale (BS) and peripheral O2 saturation (SpO2). HR, RR and SpO2 were also monitored minute by minute during the test, such that a drop in SpO2 below 87% or rise in RR to more than 75% of age-predicted maximal HR were used as criteria for interrupting the test. The test initiated with the treadmill traveling at 2.5 km/h. Every 30 seconds of the test, the examiner asked the patient if the speed could be increased, maintained or decreased, and patients answered using previously agreed upon signals. The speed could not exceed 7 km/h and if it was reached, the question would be re-asked in the next 30 seconds to determine whether the speed would be maintained or reduced. After the test, the walk distance (WD) on the treadmill was recorded.
The 6MWT performed with NIV followed the same procedures described above. However, before the test, patients were submitted to NIV on a BiPAP mode (Synchrony- Respironics, Brazil) for 30 minutes, as proposed by Serra et al 15, with inspiratory airway pressure (IPAP) level of 12 cmH2O and final expiratory airway pressure (EPAP) of 6 cmH2O, which can vary by 2 cmH2O more or less depending on the patient's comfort. In the last six minutes of BiPAP the patient performed the 6MWT with the ventilatory support.
Optoelectronic plethysmography: The individual was sitting with 89 retro-reflective sensors at specific thoracic and abdominal points. Eight cameras were arranged around the patient for a three-minute film of quiet breathing. The images were analyzed in a three-dimensional polyhedric model using OEP capture software (BTS Bioengineering, Italy). The following variables were assessed by OEP (BTS Bioengineering, Italy) before and after both tests, with and without NIV: tidal volume, pulmonary rib cage volume, abdominal rib cage and abdominal volume (VC, Vrcp Vrca, Vab), respiratory rate (RR), inspiratory time (Ti), expiratory time (Te) total ventilatory cycle time (Ttot) and duty cycle, which represents the Ti/Ttot ratio.
Spirometry: Spirometry was conducted using a Microloop MK 8 spirometer (Micro Medical, England) to assess pulmonary function response, considering a 20-minute rest period between the spirometric test and 6MWT. Three reproducible forced maneuvers that met American Thoracic Society criteria were performed. The highest values obtained for forced expiratory volume in the first minute (FEV1), forced vital capacity (FVC), forced vital capacity between 25-75% of FVC (FEF 25-75) were recorded for analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| With noninvasive ventilation | Experimental | Device: Noninvasive VentilationWhen patients do the six minute walk test with the noninvasive ventilation. |
| Without noninvasive ventilation | No intervention | –When patients do the six minute walk test without noninvasive ventilation. |
Who may qualify
- Ages
- 7 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- clinical diagnosis of Cystic Fibrosis
- FEV1< 80% of predicted
- age between 7 and 16 years
- clinically stable patients
- no history of hospitalization for respiratory failure in the last three months
Key exclusion criteria (7 listed)
- recent history of hemoptysis
- pneumothorax or evidence of emphysomatous bubbles detected by chest X-ray
- Burkholderia cepacia colonization
- the need for more than two physiotherapy sessions per day
- gastroesophageal reflux
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Noninvasive VentilationAlso: BiLEVEL, Noninvasive ventilatory supportA randomized plan define the order in which patients would execute the 6MWT, with or without NIV. | Device | With noninvasive ventilation |
Primary outcome
Walk Distance (WD) on six minute walk test (6MWT)
Time frame: 2 days
Patients allocated to group 1 (G1) initiated the 6MWT without noninvasive ventilation (NIV) to subsequently perform the test with ventilatory support, since those allocated to group 2 (G2) underwent the tests in reverse order. Rest period between tests: 24 - 48 hours. At the end of the test, the walk distance on a treadmill is recorded.
5 secondary outcomes
Forced expiratory volume in the first second (FEV1)
Time frame: 2 days
Rib cage volumes
Time frame: 2 days
Forced vital capacity (FVC)
Time frame: 2 days
Forced expiratory flow of 25% to 75% of FVC (FEF 25-75)
Time frame: 2 days
Respiratory cicle time
Time frame: 2 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2013.
- Results publication: PubMed 1758504Engelsbel S, Kuijper EJ, Dankert J, Braat MC, Egas J. [A tuberculosis project in Ecuador]. Ned Tijdschr Geneeskd. 1991 Dec 21;135(51):2428-32. Dutch.
- Results publication: PubMed 9338435Aliverti A, Cala SJ, Duranti R, Ferrigno G, Kenyon CM, Pedotti A, Scano G, Sliwinski P, Macklem PT, Yan S. Human respiratory muscle actions and control during exercise. J Appl Physiol (1985). 1997 Oct;83(4):1256-69. doi: 10.1152/jappl.1997.83.4.1256.
- Related InfoLink provided by the sponsor.
Related trials for Cystic Fibrosis
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
Cystic Fibrosis - Complete
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Noninvasive Ventilation in people with Cystic Fibrosis, run by Universidade Federal de Pernambuco at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Walk Distance (WD) on six minute walk test (6MWT) (time frame: 2 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01987271, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2013.